Showing 751-755 of 755 results for "".
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
https://practicaldermatology.com/programs/cme/directed-relief-in-ckd-ap-linking-targeted-therapy-to-clinical-outcomes/14967/Join our experts’ discussion to learn how to significantly improve quality of life for your patients with chronic kidney disease-associated pruritus.Pipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigWhy We Should Be PRO Patients With CKD-Associated Pruritus
https://practicaldermatology.com/programs/cme/why-we-should-be-pro-patients-with-ckd-associated-pruritus/14968/Our experts offer tips to effectively use Patient-Reported Outcome Measures (PROMs) in clinical practice to improve health outcomes in patients with CKD-aP.Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation
https://practicaldermatology.com/programs/cme/taking-the-patient-centered-approach-to-mycophenolate-risk-mitigation-mycophenolate-risk-mitigation/16628/Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation.Holding Court in Melanoma: Choosing the Optimal Adjuvant Treatment Approach for Stage III BRAF-Mutant Melanoma
https://practicaldermatology.com/programs/cme/holding-court-in-melanoma-choosing-the-optimal-adjuvant-treatment-approach-for-stage-iii-braf-mutant-melanoma/15435/How can we choose the best adjuvant treatment strategy for melanoma patients with BRAF-activating tumors? Don’t miss this series.
- Previous
- Next